Trial NCT00066807

View at ClinicalTrials.gov 
Org. Study IDs: IBCSG 26-02 / BIG 4-02
Secondary IDs: 2005-002626-59 CDR0000318832 EU-20401 NABCI-IBCSG-26-02

Last trial update was posted on 2016-10-28

MeSH Interventions

Epirubicin Exemestane Tamoxifen Triptorelin Pamoate

MeSH Conditions

Breast Neoplasms

Other Conditions

Breast Cancer

Stopping Reasons

Poor accrual, patients were followed until completion of 5 yrs treatment

Limitations And Caveats

Trial terminated early due to poor accrual. Adverse event data is available ONLY for selected Grade 3-5 AEs for chemotherapy arm. 25 of 29 patients were co-enrolled in TEXT (IBCSG 25-02), which reports AEs and outcomes of endocrine therapy.

Result Publications

N/A

Annotations

Category Annotations
No annotators decided on categories yet

Intervention Annotations
# Outdated Intervention Condition
Name Route DrugBank ID